Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Los Angeles, CA
NPI: 1275578957Primary Employer
USC Care Medical Group, Inc
keckmedicine.org
HQ Phone
Get M.D. Ann's Phone NumberMobile
Get M.D. Ann's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1993 - 2026
American Board of Internal Medicine
Medical Oncology
Harvard Medical School
hms.harvard.edu
Medical School
Until 1987
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
Fellowship • Hematology and Medical Oncology
1990 - 1993
Mass General Brigham/Brigham and Women's Hospital
Residency • Internal Medicine
1987 - 1990
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 142 | 456 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 40 | 75 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 32 | 37 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 26 | 74 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 21 | 21 |
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Authors: Jacob Laubach, Andrzej Jakubowiak
Publication Date: 2016-01-21
A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation.
Authors: Dan Douer, Allen Yang, Casey O'Connell
Publication Date: 2010-11
B cell non-Hodgkin's lymphoma: rituximab safety experience
Authors: @ValidYN, LastName, ForeName, Initials, AffiliationInfo
Journal: Arthritis Res Ther
Publication Date: 2005-05-18
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Placebo Administration, DRUG: Dasatinib Anhydrous
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: laboratory biomarker analysis, PROCEDURE: peripheral blood stem cell transplantation, DRUG: cytarabine, DRUG: mitoxantrone hydrochloride
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, BIOLOGICAL: Ipilimumab, BIOLOGICAL: Rituximab